Evaxion A (EVAX) EBITDA Margin (2024 - 2025)
Evaxion A posted quarterly EBITDA Margin of 40.34% for Q3 2025, up 9771.0% year-on-year from 0.41% in Q3 2024, and up 100.36% on a QoQ basis from 11248.65% in Q2 2025.
Evaxion A (EVAX) has 2 years of EBITDA Margin data on file, last reported at 40.34% in Q3 2025.
- For the quarter ending Q3 2025, EBITDA Margin rose 9771.0% year-over-year to 40.34%; the trailing twelve-month figure through Mar 2026 stood at 119.68% (up 35991.0% YoY), and the FY2025 full-year result was 122.66%, up 31789.0% from the prior year.
- EBITDA Margin for Q3 2025 stood at 40.34%, up from 11248.65% in the prior quarter.
- Across five years, EBITDA Margin topped out at 40.34% in Q3 2025 and bottomed at 11248.65% in Q2 2025.
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) | EBITDA Margin (Qtr) |
|---|---|---|---|---|---|
| 1 | Quantum Biopharma | 961,148.99 Bn | 961,148.98 Bn | - | - |
| 2 | Alterity Therapeutics | 744,933.29 Bn | 744,933.26 Bn | - | - |
| 3 | Legend Biotech | 2,540.00 Bn | 2,539.71 Bn | 242.10 Mn | -6.43% |
| 4 | Nanobiotix | 2,199.85 Bn | 2,199.78 Bn | - | - |
| 5 | Akari Therapeutics | 1,635.88 Bn | 1,635.88 Bn | - | - |
| 6 | Vertex Pharmaceuticals | 111.32 Bn | 104.07 Bn | 2.59 Bn | 38.10% |
| 7 | Evaxion A | 62.56 Bn | 62.54 Bn | - | - |
| 8 | Regeneron Pharmaceuticals | 62.55 Bn | 53.79 Bn | 3.31 Bn | 18.35% |
| 9 | Alnylam Pharmaceuticals | 39.57 Bn | 36.56 Bn | 959.66 Mn | 17.24% |
| 10 | Revolution Medicines | 32.39 Bn | 32.39 Bn | - | - |
Historic Data
Download Data| Date | Value |
|---|---|
| Sep 30, 2025 | 40.34% |
| Jun 30, 2025 | -11,248.65% |
| Dec 31, 2024 | -3,298.36% |
| Sep 30, 2024 | -57.37% |
| Jun 30, 2024 | -4,006.49% |
| Mar 31, 2024 | -8,619.61% |